Related Experiment Videos
[Tumor markers in gynecologic malignancies].
Gan No Rinsho. Japan Journal of Cancer Clinics
|May 1, 1983
Summary
Radioimmunoassay (RIA) for human chorionic gonadotropin (hCG) beta subunit C-terminal peptide offers specific detection for trophoblastic diseases. This method aids in confirming remission and detecting early recurrence, improving patient monitoring.
Area of Science:
- Oncology
- Biochemistry
- Immunology
Context:
- Human chorionic gonadotropin (hCG) is a key biomarker for trophoblastic diseases.
- Accurate and specific detection methods are crucial for disease management.
- Existing markers may lack specificity or sensitivity for early detection.
Purpose:
- To evaluate a radioimmunoassay (RIA) for the C-terminal peptide of the hCG-beta subunit.
- To assess the specificity and sensitivity of this RIA for detecting hCG.
- To determine its utility in monitoring trophoblastic disease remission and recurrence.
Summary:
- A specific RIA for the hCG-beta subunit C-terminal peptide detects hCG at low levels (0.5 IU/day urine, 0.5 mIU/ml serum) without cross-reactivity with luteinizing hormone.
- This assay is valuable for confirming complete remission of trophoblastic diseases.
- It enables early detection of disease recurrence.
Impact:
- Provides a highly specific assay for monitoring trophoblastic disease, enhancing patient care.
- Facilitates timely intervention by enabling early detection of recurrence.
- Complements other tumor markers like alpha-fetoprotein and lactic dehydrogenase for comprehensive cancer monitoring.